AcelRx Q1 net loss $8.2M; DSUVIA divestiture closed, Niyad EUA submitted

TALPHERA, INC.

Net loss $8.2M ($0.75/share) vs $8.7M loss in Q1 2022; cash $13.4M at March 31, 2023.
DSUVIA divestiture to Alora closed April 3; 15% royalty on commercial sales, 75% on DoD, up to $116.5M milestones.
EUA request for Niyad (nafamostat mesylate) submitted to FDA April 27; registrational study expected H2 2023.
Combined R&D and SG&A expenses $5.3M, up from $4.9M, driven by legal and Niyad costs.
Recognized $7.0M impairment on net assets held for sale from DSUVIA discontinued operations.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TALPHERA, INC. reported the first quarter of 2023 results: net income $8.2 million, EPS $0.75 per basic and diluted share.

Period: the first quarter of 2023
Net income: $8.2 million
EPS: $0.75 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss attributable to common shareholders for the first quarter of 2023 was $8.2 million, or $0.75 per basic and diluted share, compared to a net loss of $8.7 million, or $1.19 per basic and diluted share, for the first quarter of 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-013597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.